IN2012DN03338A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03338A
IN2012DN03338A IN3338DEN2012A IN2012DN03338A IN 2012DN03338 A IN2012DN03338 A IN 2012DN03338A IN 3338DEN2012 A IN3338DEN2012 A IN 3338DEN2012A IN 2012DN03338 A IN2012DN03338 A IN 2012DN03338A
Authority
IN
India
Prior art keywords
factor
antibody
antigen binding
binding fragment
crystal structure
Prior art date
Application number
Other languages
English (en)
Inventor
Menno Van Lookeren Campagen
Christian Wiesmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2012DN03338A publication Critical patent/IN2012DN03338A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
IN3338DEN2012 2009-11-04 2010-11-04 IN2012DN03338A (enExample)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28046009P 2009-11-04 2009-11-04
US28171609P 2009-11-20 2009-11-20
PCT/US2010/055509 WO2011057014A1 (en) 2009-11-04 2010-11-04 Co-crystal structure of factor d and anti-factor d antibody

Publications (1)

Publication Number Publication Date
IN2012DN03338A true IN2012DN03338A (enExample) 2015-10-23

Family

ID=43303899

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3338DEN2012 IN2012DN03338A (enExample) 2009-11-04 2010-11-04

Country Status (14)

Country Link
US (1) US20110165648A1 (enExample)
EP (1) EP2496695A1 (enExample)
JP (1) JP2013509866A (enExample)
KR (1) KR20120120153A (enExample)
CN (1) CN102666850A (enExample)
AR (1) AR078886A1 (enExample)
BR (1) BR112012011607A2 (enExample)
CA (1) CA2782481A1 (enExample)
IN (1) IN2012DN03338A (enExample)
MX (1) MX2012005430A (enExample)
RU (1) RU2012122700A (enExample)
TW (1) TW201121993A (enExample)
WO (1) WO2011057014A1 (enExample)
ZA (1) ZA201202602B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20170001A (es) * 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
US10093978B2 (en) 2013-08-12 2018-10-09 Genentech, Inc. Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
ES2819217T3 (es) 2013-09-08 2021-04-15 Kodiak Sciences Inc Conjugados de polímeros iónicos dipolares y factor VIII
MA39934A (fr) 2014-05-01 2017-03-08 Hoffmann La Roche Variants d'anticorps anti-facteur d et leurs utilisations
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20210013299A (ko) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
CA3003647A1 (en) * 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody formulations
WO2017075252A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
GB2553252B (en) * 2016-01-20 2019-07-31 Vitrisa Therapeutics Inc Aptamers that block the catalytic cleft of complement Factor D
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
WO2018191548A2 (en) * 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
US6291160B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291161B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
US6291159B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JP3127158B2 (ja) 1989-10-05 2001-01-22 オプテイン，インコーポレイティド 新規の遺伝子及びポリペチドの無細胞合成並びに単離
US5244800A (en) * 1990-04-27 1993-09-14 The Uab Research Foundation Crystals of human complement factor d that are triclinic
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0617706T3 (da) 1991-11-25 2001-11-12 Enzon Inc Multivalente antigenbindende proteiner
DK1024191T3 (da) 1991-12-02 2008-12-08 Medical Res Council Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
DK2097455T3 (en) * 2006-11-02 2014-12-15 Genentech Inc HUMANIZED ANTI-FACTOR D ANTIBODIES
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) * 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados

Also Published As

Publication number Publication date
CN102666850A (zh) 2012-09-12
TW201121993A (en) 2011-07-01
KR20120120153A (ko) 2012-11-01
EP2496695A1 (en) 2012-09-12
MX2012005430A (es) 2012-06-19
BR112012011607A2 (pt) 2020-06-02
JP2013509866A (ja) 2013-03-21
ZA201202602B (en) 2013-06-26
WO2011057014A1 (en) 2011-05-12
RU2012122700A (ru) 2013-12-10
US20110165648A1 (en) 2011-07-07
CA2782481A1 (en) 2011-05-12
AR078886A1 (es) 2011-12-07

Similar Documents

Publication Publication Date Title
IN2012DN03338A (enExample)
EP2566890A4 (en) ANTI-PAI-1 ANTIBODIES AND METHOD FOR THEIR USE
MX2018010572A (es) Inmunoglobulinas heterodimericas.
CY1122978T1 (el) Αντισωματα εναντι-vla-4
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
MX2013001473A (es) Anticuerpos contra il-18r1 y usos de los mismos.
PH12013502230A1 (en) Multispecific antibodies
PH12013501339A1 (en) Anti-pcsk9 antibodies and methods of use
EP2560684A4 (en) FIBRONECTIN TYPE III DOMAIN MULTIMERIC SCAFFOLDS
MX356218B (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5.
EA201201000A1 (ru) Способы лечения колоректального рака
PH12018500046A1 (en) Anti-mesothelin antibodies and immunoconjugates
SI3002298T1 (sl) Monoklonska protitelesa proti faktorju XI in postopki njihove uporabe
PH12013500277A1 (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
BR112013020500A2 (pt) anticorpo isolado, recombinante ou purificado
CY1121167T1 (el) Βελτιωμενα αντισωματα εναντι της ανθρωπινης φρακταλκινης και χρησεις αυτων
MX336323B (es) Anticuerpos de anti-poliubiquitina y metodos de uso.
EA201490778A1 (ru) АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ
MX2011010012A (es) NUEVOS ANTICUERPOS ANTI-A5ß1 Y SUS USOS.
PH12013500933A1 (en) Methods and compositions for neural disease immunotherapy
MY161868A (en) Anti-bv8 antibodies and uses thereof
PH12013500616A1 (en) Antibody compositions and methods of use
WO2010017595A8 (en) Variant domain antibodies
PH12013500432A1 (en) Anti-vegfr-3 antibody compositions
TN2011000041A1 (en) Compositions and methods for antibodies targeting complement protein c5